hellfire 50

5-Amino-1MQ (50 mg Vial) Dosage Protocol

5-Amino-1MQ dosage protocols center on this selective, cell-permeable NNMT (Nicotinamide N-methyltransferase) inhibitor studied for its potential to support fat metabolism, preserve lean muscle mass, and elevate intracellular NAD+ levels^[1]^[2]. By blocking NNMT, 5-Amino-1MQ may help restore cellular energy balance and activate SIRT1 pathways associated with metabolic efficiency^[3]. This educational protocol presents a subcutaneous injection approach to maximize bioavailability from the 50 mg vial format.

Reconstitute: Add 4.0 mL bacteriostatic water → 12.5 mg/mL concentration.
Typical daily range: 2.5–5 mg once or twice daily (subcutaneous).
Easy measuring: At 12.5 mg/mL, 1 unit = 0.01 mL = 0.125 mg (125 mcg) on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks.

Educational guide for reconstitution and weekly dosing

Subcutaneous Protocol (4 mL = 12.5 mg/mL)

Phase	Daily Dose (mg)	Units (per injection) (mL)
Days 1–2 (Tolerance)	2.5 mg once daily	20 units (0.20 mL)
Days 3+ (Standard)	5 mg once daily	40 units (0.40 mL)
Alternative BID	2.5 mg twice daily	20 units (0.20 mL) × 2

Frequency: Inject once or twice daily subcutaneously. Due to the compound’s plasma half-life of approximately 3.8–6.9 hours^[4], twice-daily (BID) dosing may provide more sustained NNMT inhibition. A single 50 mg vial provides 10–20 days of research material at these doses.

Reconstitution Steps

Remove the vial from freezer storage (−20 °C / −4 °F) and allow to equilibrate at room temperature for 15–20 minutes.
Draw 4.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved—solution should be clear (do not shake).
Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 2–4 weeks.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Plan based on research duration using the 50 mg vial format at 5 mg/day.

5-Amino-1MQ Vials (50 mg each):
- 1 week (5 mg/day) ≈ 1 vial
- 2 weeks (5 mg/day) ≈ 1 vial
- 4 weeks (5 mg/day) ≈ 2 vials
Insulin Syringes (U-100):
- Per week (once daily): 7 syringes
- Per week (BID): 14 syringes
- 4 weeks (once daily): 28 syringes
Bacteriostatic Water (10 mL bottles): Use 4.0 mL per vial for reconstitution.
- 1 week (1 vial): 4 mL → 1 × 10 mL bottle
- 2 weeks (1 vial): 4 mL → 1 × 10 mL bottle
- 4 weeks (2 vials): 8 mL → 1 × 10 mL bottle
Alcohol Swabs: One for the vial stopper + one for the injection site each administration.
- Per week (once daily): 14 swabs
- 4 weeks (once daily): 56 swabs → recommend 1 × 100-count box

Concise summary of the once-weekly regimen.

Goal: Support metabolic efficiency through NNMT inhibition, potentially enhancing fat oxidation and NAD+ levels^[1]^[2].
Schedule: Daily subcutaneous injections; each 50 mg vial provides 10–20 days of research material.
Dose Range: 2.5–5 mg once or twice daily.
Reconstitution: 4.0 mL per 50 mg vial (12.5 mg/mL) for accurate measurements.
Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F).

Suggested weekly titration approach from clinical trials.

Start: 2.5 mg once daily to assess tolerance.
Target: 5 mg once daily or 2.5 mg twice daily (BID).
Frequency: Once or twice per day (subcutaneous).
Vial Duration: Single 50 mg vial lasts 10–20 days at research doses.
Timing: Morning administration preferred; BID dosing may be split AM/PM.

Proper storage preserves peptide quality and stability.

Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable up to 24 months.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 2–4 weeks.
Allow vials to reach room temperature before reconstitution to prevent condensation and pressure issues.
Do not refreeze reconstituted solution.

Practical considerations for consistency and safety.

Use new sterile insulin syringes for each administration; dispose in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
Inject slowly; a mild stinging sensation may occur due to the quinolinium structure.
Document daily dose and site rotation to maintain consistency.
The 50 mg vial format is ideal for extended research cycles; a single vial can last 10–20 days.

5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small molecule that selectively inhibits Nicotinamide N-methyltransferase (NNMT)^[1]. NNMT is an enzyme that methylates nicotinamide (vitamin B3) using S-adenosylmethionine (SAM) as a methyl donor. In states of obesity and metabolic dysfunction, NNMT is often overexpressed in adipose tissue, depleting nicotinamide and reducing NAD+ availability^[2].

By inhibiting NNMT, 5-Amino-1MQ may spare nicotinamide for NAD+ synthesis, thereby activating SIRT1 (Sirtuin 1) pathways associated with mitochondrial biogenesis and fat oxidation^[3]. Preclinical studies indicate that NNMT knockdown or inhibition can protect against diet-induced weight gain and improve metabolic parameters without reducing food intake^[5]^[6].

Observations from preclinical and early research literature.

May support reductions in fat mass while preserving lean muscle in animal models^[5]^[6].
Associated with elevated NAD+ levels and SIRT1 activation in preclinical studies^[2]^[3].
Enhanced grip strength observed in aged mice when combined with exercise^[7].
Generally well tolerated; occasional reports of mild headache, transient jitteriness, or injection-site reactions.
Long-term human safety data not established; this compound remains investigational.

Complementary strategies for optimal metabolic outcomes.

Pair with a balanced, protein-forward diet tailored to energy needs.
Combine resistance training and aerobic activity—preclinical data suggest synergy with exercise^[7].
Prioritize sleep and stress management to support metabolic adaptation.
Consider complementary NAD+ precursors (NMN/NR) per emerging stack protocols^[8].

General subcutaneous guidance from clinical best-practice resources^[9].

Clean the vial stopper and skin with alcohol; allow to dry.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue^[10]^[11].
Do not aspirate for subcutaneous injections; inject slowly and steadily^[10].
Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy^[12].
Slow injection may minimize any stinging sensation associated with the compound.

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

References

— Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity

— Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunctions

— NNMT: a novel therapeutic target for metabolic syndrome

— LC-MS/MS assay for 5-amino-1-methylquinolinium: pharmacokinetic and oral bioavailability study

— Combined NNMT inhibition and reduced-calorie diet normalizes body composition in obese mice

— Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice

— Role of NNMT inhibition in muscle strength: enhanced grip strength with exercise

— 5-Amino-1MQ mechanism, benefits, stacking and cycling guide

— Subcutaneous drug injection review: pharmacologic considerations

— Vaccine administration: subcutaneous route (angle/site; no aspiration)

— Technique diagram and site guidance for subcutaneous injections

— Best practices for injection (asepsis, preparation, and administration)

— Bisubstrate inhibitors of NNMT with enhanced activity

— NNMT: a bad actor in fat makes good in liver

— 5-Amino-1MQ (50 mg) product page (quality and batch documentation)

Mechanism Breakdown — 3rd Party Analysis

This video provides an external overview of 5-AMINO-1MQ

External Source

Titration schedule.

Standard research titration model. Adjust under qualified clinical observation only. Not for human therapeutic use.

Phase 01

Wk 1 — 4

20 units

Once daily

Initiation · tolerance assessment

Phase 02

Wk 5 — 8

40 units

Once daily

Standard titration step

Phase 03

Wk 9 — 12

20 units

Twice daily

Maintenance evaluation

Phase 04

Wk 13+

40 units

Twice daily

Optional research extension

Research use only.

Reta20 is supplied strictly for in-vitro laboratory research and biochemical analysis. It is not intended for human consumption, diagnostic use, veterinary application or therapeutic administration of any kind.

Handling must be performed by qualified personnel in compliance with applicable institutional and jurisdictional safety standards. The information contained on this protocol sheet is provided for educational and reference purposes only and does not constitute medical advice.

Not for human use
Store at 2–8 °C, protected from light

Reconstitute under aseptic conditions
Document all research observations

Red Tier Catalogue

Explore the full British Dragon research line.

Premium-tier compounds engineered for serious metabolic, longevity and performance research programs.

hellfire 50

5-Amino-1MQ (50 mg Vial) Dosage Protocol

5-Amino-1MQ (50 mg Vial) Dosage Protocol

Table of Contents

Quickstart Highlights

Dosing & Reconstitution Guide

Subcutaneous Protocol (4 mL = 12.5 mg/mL)

Reconstitution Steps

Supplies Needed

Protocol Overview

Dosing Protocol

Storage Instructions

Important Notes

How This Works

Potential Benefits & Side Effects

Lifestyle Factors

Injection Technique

Video

Important Note

References

Mechanism Breakdown — 3rd Party Analysis

Titration schedule.

Phase 01

Wk 1 — 4

20 units

Once daily

Initiation · tolerance assessment

Phase 02

Wk 5 — 8

40 units

Once daily

Standard titration step

Phase 03

Wk 9 — 12

20 units

Twice daily

Maintenance evaluation

Phase 04

Wk 13+

40 units

Twice daily

Optional research extension

Research use only.

Red Tier Catalogue

Explore the full British Dragon research line.